---
document_datetime: 2023-09-21 21:34:30
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kyntheum-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: kyntheum-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.3151658
conversion_datetime: 2025-12-29 19:58:15.522917
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kyntheum

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0021               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 23/11/2022                          |                                             | PL                               |           |
| IB/0020              | B.II.z - Quality change - Finished product - Other variation                                     | 07/11/2022                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| R/0019              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/02/2022   | 25/04/2022   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Kyntheum in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10616 /202107 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/02/2022   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                        |
| IB/0017/G           | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.1.z - Change in immediate packaging of the | 21/06/2021   | n/a          |                          |                                                                                                                                                                                                                                                                          |
| PSUSA/10616 /202007 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/02/2021   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                        |
| IB/0015             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/07/2020   | 30/09/2020   | SmPC and PL              |                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0014             | Update of section 4.4 and 4.8 of the SmPC and relevant sections of the PL to reflect a signal of anaphylactic reaction detected in the post marketing setting. Minor updates have also been included throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 25/06/2020   | 30/09/2020   | SmPC and PL   | After reviewing the available data including case reports from post-marketing sources, clinical trials and published literature, the MAH identified a signal with one case providing evidence for a causal relationship between anaphylactic reaction and brodalumab. Considering the positive rechallenge and the temporal relationship that suggests causality, the MAH included this event as new undesirable effect in section 4.8 with a ' rare ' frequency and a warning in section 4.4. In the event of an anaphylactic reaction, or any other serious allergic reaction, administration of Kyntheum should be discontinued and appropriate therapy initiated. In addition, other changes to the SmPC were approved mainly based on updated safety data of all pooled phase 2 and 3 clinical trials in the psoriasis development programme including a deletion of a warning on reduced absolute neutrophil count, changes to frequencies of ADRs and minor changes in section 5.1 and 5.2. The Package   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10616 /201907 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                                                                                                                                                                                                     | 13/02/2020   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0013             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                             | 09/12/2019   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0011             | Update of section 5.1 of the SmPC ' Mechanism of action ' subsection with information about the inhibition of cytokine IL-17C.                                                                                                                                                                                                                               | 26/09/2019   | 30/09/2020   | SmPC          | The mechanism of action subsection of the SmPC has been updated to include that brodalumab exerts its anti- inflammatory effects in psoriasis by inhibiting signaling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                              |            |            |                  | mediated by IL-17C in addition to IL-17A and IL-17F.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|--------------------------------------------------------|
| PSUSA/10616 /201901 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                       | 11/07/2019 | n/a        |                  | PRAC Recommendation - maintenance                      |
| IB/0010             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data         | 25/04/2019 | n/a        |                  |                                                        |
| IA/0009/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 10/04/2019 | n/a        |                  |                                                        |
| PSUSA/10616 /201807 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                       | 14/02/2019 | n/a        |                  | PRAC Recommendation - maintenance                      |
| IB/0007             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                        | 11/02/2019 | n/a        |                  |                                                        |
| IB/0005/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                          | 03/10/2018 | 13/09/2019 | Labelling and PL |                                                        |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0004/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                              | 13/09/2018 | n/a        |             |                                   |
| PSUSA/10616 /201801 | Periodic Safety Update EU Single assessment - brodalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12/07/2018 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0001/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/09/2017 | 02/08/2018 | SmPC, Annex |                                   |

<div style=\"page-break-after: always\"></div>

| A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   | II, Labelling and PL   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|